Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
284 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
14-C-0156
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Prostate Cancer Hereditary
001109-C
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Participants currently recruited/enrolled
8-125 Years
NCI
Cancer Hereditary
000628-C
A Study of Prospective Monitoring of Subjects with Biochemically Recurrent Prostate Cancer Using 18F-DCFPyL
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate Cancer
000569-C
Clinical Study of Bioactivity of Low Dose Apalutamide in Prostate Cancer Patients Scheduled for Prostatectomy
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate Cancer
000309-C
A Phase II Study of N-803 Alone or in Combination with BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants with Castration Resistant Prostate Cancer
Recruitment has not started
18-125 Years
NCI
Prostate Cancer
000302-C
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate Cancer
000114-C
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination with the Immunocytokine M9241 in Localized High and Intermediate Risk Prostate Cancer Treated with Androgen Deprivation Therapy
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate Cancer
000057-C
A Phase 1 Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel
Completed Study; data analyses ongoing
18-125 Years
NCI
Prostate Cancer
22-C-0004
A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer
Participants currently recruited/enrolled
12-125 Years
NCI
Cancer Hereditary
21-C-0001
A Phase I/II Study of M9241 in Combination with Docetaxel in Adults with Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate Cancer
20-C-0013
Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
No longer recruiting/follow-up only
18-125 Years
NCI
Prostate Cancer
20-C-0012
A Phase I Study of Bintrafusp alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Metastatic Non-Prostate Genitourinary Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate Cancer
19-C-0016
Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors
Participants currently recruited/enrolled
0-125 Years
NCI
Cancer Hereditary
18-C-0017
Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate Cancer
17-C-0043
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
Participants currently recruited/enrolled
2-125 Years
NCI
Cancer Hereditary
16-CC-0098
Pilot Study of Ultrasound Guided Focal Thermal Ablation of Prostate Cancer
Clinical hold/Recruitment or enrollment suspended
18-125 Years
CC
Prostate Cancer
16-C-0107
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate Cancer
15-C-0157
Phase I/II Trial of Vandetanib in Combination with Metformin in Subjects with HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer Hereditary
15-C-0145
Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination with Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate Cancer
13-C-0016
A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults with Tumors with 1-3+ HER2/neu Expression
Completed Study; data analyses ongoing
18-125 Years
NCI
Prostate Cancer
12-C-0079
A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Prostate Cancer
11-C-0255
Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome
Participants currently recruited/enrolled
0-125 Years
NCI
Cancer Hereditary
11-C-0033
Extended Follow-up of High Ovarian Cancer Risk Cohort from 02C0268 (GOG-199)
Completed Study; data analyses ongoing
18-100 Years
NCI
Cancer Hereditary
09-C-0139
A Pilot Study of Vaccination with Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Prostate Cancer
07-C-0100
Collection of Blood from Patients with Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate Hereditary
03-C-0066
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer
Participants currently recruited/enrolled
2-125 Years
NCI
Prostate Hereditary
02-C-0268
Prospective Study of Prophylactic Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer
Completed Study; data analyses ongoing
19-100 Years
NCI
Cancer Hereditary
02-C-0212
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
Completed Study; data analyses ongoing
18-100 Years
NCI
Cancer Hereditary
02-C-0052
Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study
Participants currently recruited/enrolled
0-125 Years
NCI
Cancer Hereditary
00-H-0051
Cutaneous Tumorigenesis in Patients with Tuberous Sclerosis
Participants currently recruited/enrolled
18-90 Years
NHLBI
Cancer Hereditary
78-C-0039
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer
No longer recruiting/follow-up only
0-125 Years
NCI
Cancer Hereditary
001099-C
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-Fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
001048-I
A Phase 1/2 Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-Seronegative Persons
Recruitment has not started
18-22 Years
NIAID
Cancer
001032-C
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (
Recruitment has not started
18-125 Years
NCI
Cancer
001004-C
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon Oncosignature (R) Status
Participants currently recruited/enrolled
18-120 Years
NCI
Cancer
000975-C
Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples from Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000958-C
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
Enrolling by Invitation
18-125 Years
NCI
Cancer
000954-C
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients with Advanced Mesothelin-Expressing Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000930-C
A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-Beta Antagonist/IL-15 Protein Complex, for Advanced Pancreatic Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000821-I
An Open-Label, Single-Arm, Phase 1/2 Dose-Escalation Trial of Long-Acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia
Recruitment has not started
18-75 Years
NIAID
Cancer
000797-C
BIOLEN-PC: A Study to Establish the Feasibility of Biolen (Registered Trademark) for the Local Delivery of Bicalutamide in Patients with Prostate Cancer
Participants currently recruited/enrolled
35-125 Years
NCI
Prostate
000784-N
Assessing and Improving Quantitative Magnetic Resonance Imaging Metrics in Human Subjects
Participants currently recruited/enrolled
18-125 Years
NINDS
Prostate
000782-C
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
Recruitment has not started
18-125 Years
NCI
Cancer
000715-CH
Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy
Participants currently recruited/enrolled
4-35 Years
NICHD
Cancer
000697-H
U01 Cooperative Assessment of Late Effects for SCD Curative Therapies (COALESCE)
Participants currently recruited/enrolled
18-65 Years
NHLBI
Cancer
000692-C
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide
Participants currently recruited/enrolled
12-125 Years
NCI
Cancer
000678-C
Rare Tumors and Cancer Predisposition in Individuals and Families
Participants currently recruited/enrolled
0-125 Years
NCI
Hereditary
000666-C
A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Recruitment has not started
18-125 Years
NCI
Cancer
000644-C
Phase 1/1b Trial of ATR Inhibitor BAY 1895344 in Combination with FOLFIRI in GI Malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000633-C
Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000631-C
Investigation of the Cognitive Aftereffects of Neurotoxicity in Children and Young Adults with Relapsed/Refractory Hematologic Malignancies who Receive CAR T-cell Therapy
Recruitment has not started
5-125 Years
NCI
Cancer
000613-C
Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination with Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis after Reduced Intensity Conditioning and Peripheral Blood St
Participants currently recruited/enrolled
12-125 Years
NCI
Cancer
000611-C
A Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate Cancer
Recruitment has not started
18-125 Years
NCI
Prostate
000580-C
A Phase 1/2, Open Label Dose-Escalation and Expansion Trial of Nkt2152, an Orally Administered Hif2a Inhibitor, to Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000567-C
Phase 1 Trial of Gemcitabine Combined with the BAY 1895344 ATR Inhibitor with Expansion Cohorts in Advanced Pancreatic and Ovarian Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000545-DK
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant: A Prospective Natural History Study
Recruitment has not started
3-125 Years
NIDDK
Cancer
000516-C
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma involving the Central Nervous System
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000491-C
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000489-C
Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
Clinical hold/Recruitment or enrollment suspended
12-125 Years
NCI
Cancer
000481-C
Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
000478-C
A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by GVHD Prophylaxis with Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living with HIV (PLWH)
Participants currently recruited/enrolled
12-125 Years
NCI
Cancer
000462-C
Phase 2, Open-label, Single-arm, Window of Opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients With Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000444-H
Vaccine Responses in Patients with B Cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NHLBI
Cancer
000418-C
Phase 1/2a, Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients with Advanced Prostate Cancer
Participants currently recruited/enrolled
18-120 Years
NCI
Prostate
000404-C
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects with VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Participants currently recruited/enrolled
18-75 Years
NCI
Cancer
000359-C
Phase I/II study to reduce post-transplantation cyclophosphamide dosing for older or unfit patients undergoing bone marrow transplantation for hematologic malignancies
Participants currently recruited/enrolled
12-85 Years
NCI
Cancer
000354-C
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000337-C
Natural History Study of KSHV-Associated Multicentric Castleman's Disease
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000328-C
Bicalutamide Implants (Biolen ) with Radiation Therapy in Patients with Localized Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
000326-H
A Phase 1, Dose Escalation, Safety and Tolerability Study of NX- 2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NHLBI
Cancer
000317-C
A Phase II, Open-Label Trial of PT-112 in Subjects with Thymoma and Thymic Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000307-C
Phase II Study Evaluating the Efficacy of M9241 in Combination with Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects with Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000303-C
A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide Vs. Temozolomide and Olaparib For Advanced Pheochromocytoma And Paraganglioma
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000237-C
Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis from Colorectal, Appendiceal, Small Bowel, Gastric, Ovarian, or Other Gynecologic Primary Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000193-C
Phase 1 Study of Copanlisib with Dose-adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and other High-Grade B-cell Lymphomas
Clinical hold/Recruitment or enrollment suspended
18-125 Years
NCI
Cancer
000176-C
A Phase I/II Trial of Lurbinectedin with Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000144-C
A Phase I/II Study of Sacituzumab Govitecan plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000123-CC
Evaluation of Atherosclerotic Plaques in Abdominal CT Studies
No longer recruiting/follow-up only
0-125 Years
CC
Prostate
000115-C
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants with Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants with Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster D
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000103-C
A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000096-C
A Phase II study of Immunotherapy Combination: Irradiated PD-L1 CAR-NK cells plus Pembrolizumab plus N-803 for Subjects with Recurrent/Metastatic Gastric or Head and Neck Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
000092-C
Phase 1/2 study of Vincristine and Temozolomide in Combination with PEN-866 for Adolescents and Young Adults with Relapsed or Refractory Solid Tumors
Recruitment has not started
12-39 Years
NCI
Cancer
000081-C
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
Completed Study; data analyses ongoing
2-125 Years
NCI
Cancer
000079-DK
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
Participants currently recruited/enrolled
18-125 Years
NIDDK
Cancer
000062-C
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants with Pleural Mesotheliomas, or Pleural Effusions from Cancers Expressing Mesothelin
Participants currently recruited/enrolled
18-120 Years
NCI
Cancer
000048-C
A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
000046-C
Omics of Cancer: OncoGenomics
Recruitment has not started
0-125 Years
NCI
Cancer
000045-C
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and other KK-LC-1 Positive Epithelial Cancers
Participants currently recruited/enrolled
18-120 Years
NCI
Cancer
22-I-0008
A Single Arm Open Label Phase 2 Trial of Anti-CD4 Antibody UB-421 in Combination with Optimized Background Antiretroviral Therapy in Patients with Multi-Drug Resistant HIV-1 Infection
Recruitment has not started
18-125 Years
NIAID
Cancer
21-C-0023
A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies With or Without HIV
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
21-C-0017
Magnetic Resonance Image (MRI) Guided High Energy Ultrasound for Focal Prostate Cancer Ablation
Recruitment has not started
18-125 Years
NCI
Prostate
21-C-0015
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
21-C-0012
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
21-C-0007
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
20-HG-0025
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects with GNE Myopathy
Participants currently recruited/enrolled
18-125 Years
NHGRI
Hereditary
20-H-0016
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Cancer
20-DC-0047
Natural History of Autosomal Dominant Hearing Loss
Participants currently recruited/enrolled
3-99 Years
NIDCD
Hereditary
20-CH-0126
Data Collection Study of Pediatric and Adolescent Gynecology Conditions
Participants currently recruited/enrolled
0-125 Years
NICHD
Cancer
20-C-0167
Close Assessment and Testing for Chronic Graft-vs-Host Disease (CATCH Study)
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
20-C-0164
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
20-C-0155
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination with BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) with CV301 TRICOM in Advanced Solid Tumors (STAT)
No longer recruiting/follow-up only
18-125 Years
NCI
Cancer
20-C-0154
Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
20-C-0152
Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
20-C-0149
Phase II Trial of Olaparib (LYNPARZA) plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas that Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
20-C-0138
Phase II Trial of Combination Immunotherapy in Subjects with Advanced Small Bowel and Colorectal Cancers
No longer recruiting/follow-up only
18-125 Years
NCI
Cancer
20-C-0130
A Feasibility Study Investigating the Use of Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain
Enrolling by Invitation
12-125 Years
NCI
Cancer
20-C-0127
A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), dexamethasone, and lenalidomide (RAdR) for relapsed/refractory T-cell malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
20-C-0121
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
20-C-0107
Clinical, Genetic, and Epidemiologic Study of Children and Adults with RASopathies
Participants currently recruited/enrolled
0-125 Years
NCI
Cancer
20-C-0106
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients with BAP1 Tumor Predisposition Syndrome
Participants currently recruited/enrolled
30-125 Years
NCI
Cancer
20-C-0104
Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination with Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects with HPV Positive Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
20-C-0069
A First-In-Human Phase I Single-Agent Dose-Escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
20-C-0051
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Genitourinary Malignancies Branch Studies
Enrolling by Invitation
18-125 Years
NCI
Cancer
20-C-0045
Phase I/II Trial of Combination Immunotherapy in Subjects with Advanced HPV Associated Malignancies
No longer recruiting/follow-up only
18-125 Years
NCI
Cancer
20-C-0041
Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Enrolling by Invitation
1-125 Years
NCI
Cancer
20-C-0022
Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
20-C-0011
Phase 1 Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
20-C-0010
Phase II Trial of Radium-223 in Biochemically Recurrent Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
20-C-0009
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
20-C-0006
A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
19-H-0139
Investigation of the Natural Progression of Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance.
Participants currently recruited/enrolled
18-125 Years
NHLBI
Cancer
19-C-0143
A Phase II Study Using the Administration of Autologous T-Cells Engineered using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic Cancer
Participants currently recruited/enrolled
18-70 Years
NCI
Cancer
19-C-0137
A Phase II Study of Ipilimumab, Cabozantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC)
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
19-C-0127
A Phase II Study of LMB-100 Followed by Pembrolizumab in the Treatment of Adults with Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
No longer recruiting/follow-up only
18-125 Years
NCI
Cancer
19-C-0117
A Phase 1 / 2 Single Arm Open-label Clinical Trial of Gavocabtagene Autoleucel (gavo-cel) in Patients with Advanced Mesothelin Expressing Cancer
Participants currently recruited/enrolled
18-120 Years
NCI
Cancer
19-C-0112
Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies
Participants currently recruited/enrolled
12-125 Years
NCI
Cancer
19-C-0104
A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
19-C-0076
A Phase 1 Study of Interleukin-15 in Combination with Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
19-C-0062
A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined with Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
19-C-0049
Long Term Follow-up of Mesothelioma Patients and Their Family Members with Germline Mutations in BAP1 and Other Genes
Participants currently recruited/enrolled
2-125 Years
NCI
Cancer
19-C-0042
A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
Cancer
19-C-0041
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
19-C-0040
Natural History Study of Men at High Genetic Risk for Prostate Cancer
Participants currently recruited/enrolled
30-75 Years
NCI
Prostate
19-C-0039
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
19-C-0033
Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
19-C-0023
A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair Defects
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
19-C-0017
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Participants currently recruited/enrolled
18-70 Years
NCI
Cancer
18-I-0092
A Phase 2, Open-Label Study to Assess the Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in Patients with Idiopathic CD4 T cell Lymphocytopenia
Participants currently recruited/enrolled
18-70 Years
NIAID
Cancer
18-C-0143
A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
18-C-0138
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma.
No longer recruiting/follow-up only
18-125 Years
NCI
Hereditary
18-C-0122
Phase 1B Study of Copanlisib in Combination with Nivolumab or with Nivolumab and Ipilimumab
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
18-C-0110
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
18-C-0078
A Phase I/II Study of Immunotherapy Combination BN-Brachyury vaccine, M7824, N-803 and Epacadostat (QuEST1)
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
18-C-0076
Bicalutamide With or Without Metformin for Biochemical Recurrence in Prostate Cancer Patients (BIMET-1)
Completed Study; data analyses ongoing
18-85 Years
NCI
Prostate
18-C-0062
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Completed Study; data analyses ongoing
2-30 Years
NCI
Cancer
18-C-0059
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-39 Years
NCI
Cancer
18-C-0058
A Pilot Study to Evaluate the Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
18-C-0056
Phase II Trial of M7824 in Subjects with HPV Associated Malignancies
No longer recruiting/follow-up only
18-125 Years
NCI
Cancer
18-C-0049
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients with Metastatic Cancer
Participants currently recruited/enrolled
18-72 Years
NCI
Cancer
18-C-0034
A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
18-C-0033
Phase I Study of Recombinant Interleukin 15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects with Refractory Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
18-C-0028
A Phase I Trial of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
18-C-0005
Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
17-N-0145
PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection
Completed Study; data analyses ongoing
18-120 Years
NINDS
Cancer
17-DC-0138
Observational Study of Hearing Loss and the Effects of Statin Drugs in Head and Neck Squamous Cell Carcinoma Patients Treated with Cisplatin Chemoradiation
Completed Study; data analyses ongoing
18-125 Years
NIDCD
Cancer
17-C-0174
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
17-C-0158
A Feasibility Study of Mobile Sensor Technologies to Assess General Symptomology of Cancer Patients
Enrolling by Invitation
18-125 Years
NCI
Prostate
17-C-0153
Phase I Trial of Image Guided Focally Dose Escalated Prostate SBRT for Locally Recurrent Prostate Cancer after Prior Radiotherapy
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
17-C-0149
Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL),and Other Extranodal Diffuse Large B-cell Lymphomas
No longer recruiting/follow-up only
18-125 Years
NCI
Cancer
17-C-0140
Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas
Completed Study; data analyses ongoing
18-99 Years
NCI
Cancer
17-C-0125
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Participants currently recruited/enrolled
12-125 Years
NCI
Cancer
17-C-0117
A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of PEN-866 in Advanced Solid Malignancies
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
17-C-0109
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
Enrolling by Invitation
18-125 Years
NCI
Prostate
17-C-0102
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers
Participants currently recruited/enrolled
18-99 Years
NCI
Cancer
17-C-0090
DART: Dual Anti-CTLA-4 And Anti-Pd-1 Blockade In Rare Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
17-C-0089
Evaluation of 18F-DCFPyL PSMA- versus 18F-NaF-PET imaging for Detection of Metastatic Prostate Cancer
Enrolling by Invitation
18-125 Years
NCI
Prostate
17-C-0086
An Open-label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
No longer recruiting/follow-up only
18-125 Years
NCI
Hereditary
17-C-0070
Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer with Positive Peritoneal Cytology
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
17-C-0066
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma after Progression on Platinum-Based Chemotherapy
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
17-C-0044
Prospective Evaluation and Molecular Profiling in Patients with Gastric Tumors
Participants currently recruited/enrolled
2-125 Years
NCI
Cancer
17-C-0034
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab with and without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
17-C-0011
Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
17-C-0007
Phase I/II Study of PROSTVAC in Combination with Nivolumab in Men with Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
16-CC-0049
A Phase II Study Using LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors During Treatment with Transarterial Embolization (TAE) Alone or Combined with Thermal Ablation
Enrolling by Invitation
18-125 Years
CC
Cancer
16-C-0154
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
16-C-0138
Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects for the Expansion of T Cells for Adoptive Cell Therapy
Participants currently recruited/enrolled
18-99 Years
NCI
Cancer
16-C-0131
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing Cancers
Participants currently recruited/enrolled
18-70 Years
NCI
Cancer
16-C-0128
A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
16-C-0092
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib (AZD9291, Tagrisso)
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
16-C-0088
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritonea
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
16-C-0087
Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor in Combination with Cisplatin in Patients with Refractory Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
16-C-0073
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
16-C-0061
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
16-C-0048
Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer
No longer recruiting/follow-up only
18-125 Years
NCI
Prostate
16-C-0035
Prostvac in Patients with Biochemically Recurrent Prostate Cancer
No longer recruiting/follow-up only
18-125 Years
NCI
Prostate
16-C-0010
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
15-N-0175
An Open-Label, Phase 1b Safety and Efficacy Trial of Periganglionic Resiniferatoxin for the Treatment of Intractable Pain due to Cancer-induced Bone Pain
Recruitment has not started
18-150 Years
NINDS
Cancer
15-H-0155
Hereditary Parkinson Disease Natural History Protocol
Completed Study; data analyses ongoing
18-80 Years
NHLBI
Hereditary
15-C-0205
Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients with Clinically Localized Prostate Cancer Undergoing Active Surveillance
Completed Study; data analyses ongoing
18-99 Years
NCI
Prostate
15-C-0200
Molecular Analysis for Therapy Choice (MATCH) (EAY131)
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
15-C-0150
A Phase I/II Trial of Topotecan with VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers
No longer recruiting/follow-up only
18-125 Years
NCI
Cancer
15-C-0141
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in CAR T-Cell Studies
Enrolling by Invitation
18-125 Years
NCI
Cancer
15-C-0124
Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
No longer recruiting/follow-up only
18-125 Years
NCI
Prostate
15-C-0076
A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139
Completed Study; data analyses ongoing
18-125 Years
NCI
Prostate
15-C-0075
A Randomized, Placebo-Controlled Phase II Study of Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men with Stage D0 Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Prostate
15-C-0029
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-39 Years
NCI
Cancer
15-C-0028
Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
Enrolling by Invitation
1-99 Years
NCI
Cancer
14-I-0185
A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients with WHIM Syndrome.
Completed Study; data analyses ongoing
10-75 Years
NIAID
Cancer
14-C-0161
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
14-C-0131
A Phase II, Open-Label Study in Patients With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
14-C-0105
Tissue Procurement and Natural History Study of Patients with Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
14-C-0037
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Hereditary
14-C-0036
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination with PANVAC[TM] Versus BCG Given Alone in Adults with High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 I
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
14-C-0015
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Completed Study; data analyses ongoing
18-125 Years
NCI
Prostate
13-N-0135
Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP)
Completed Study; data analyses ongoing
18-125 Years
NINDS
Cancer
13-H-0116
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Participants currently recruited/enrolled
4-125 Years
NHLBI
Cancer
13-C-0202
Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing Cancers
Participants currently recruited/enrolled
2-125 Years
NCI
Cancer
13-C-0176
Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors
Participants currently recruited/enrolled
2-125 Years
NCI
Cancer
13-C-0153
A Phase II Trial of Enzalutamide in Combination with PSA-TRICOM in Patients with Non-Metastatic Castration Sensitive Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Prostate
13-C-0152
A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults with Refractory Solid Tumors
Completed Study; data analyses ongoing
2-29 Years
NCI
Cancer
13-C-0146
A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men with Metastatic Castration Resistant Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Prostate
13-C-0131
Inpatient Hospice with Procurement of Tissue on Expiration in Thoracic Malignancies, Bladder Cancer, Ovarian Cancer, Epithelial Cancer and Patients Treated with an Adoptive Cellular Therapy
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
13-C-0119
Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
13-C-0105
Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
Completed Study; data analyses ongoing
18-120 Years
NCI
Cancer
12-N-0095
Clinical and Molecular Manifestations of Neuromuscular and Neurogenetic Disorders of Childhood
Participants currently recruited/enrolled
0-125 Years
NINDS
Hereditary
12-H-0064
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
Participants currently recruited/enrolled
4-75 Years
NHLBI
Cancer
12-H-0035
A Phase II study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and are Older than 65 or have a 17p Deletion
No longer recruiting/follow-up only
18-125 Years
NHLBI
Cancer
12-C-0205
A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Prostate
12-C-0118
A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic Chemotherapy
No longer recruiting/follow-up only
18-100 Years
NCI
Cancer
12-C-0112
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults with B Cell Malignancies
Completed Study; data analyses ongoing
1-30 Years
NCI
Cancer
12-C-0081
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
No longer recruiting/follow-up only
18-125 Years
NCI
Cancer
12-C-0066
Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
11-NR-0014
Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and Cancer Survivors
Participants currently recruited/enrolled
18-125 Years
NINR
Prostate
11-HG-0218
A Natural History Study of Patients with GNE Myopathy and GNE-Related Diseases
Participants currently recruited/enrolled
4-80 Years
NHGRI
Hereditary
11-C-0247
A Randomized Phase II Study of Tecemotide in Combination with Standard Androgen Deprivation Therapy and Radiation Therapy for untreated, intermediate and High Risk Prostate Cancer Patients
Completed Study; data analyses ongoing
18-100 Years
NCI
Prostate
11-C-0242
Collection of Blood from Patients with Cancer, Other Tumors, or Tumor Predisposition Syndromes for Analysis of Genetic Differences in Drug Disposition
Participants currently recruited/enrolled
3-125 Years
NCI
Prostate
11-C-0220
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) Incorporating Pilot Evaluation of KSHV Targeted Therapies
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
11-C-0140
A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
11-C-0136
Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults with Molecular Imaging Evaluation
Completed Study; data analyses ongoing
2-55 Years
NCI
Cancer
11-C-0112
Acquisition of Blood and Tumor Tissue Samples from Patients with Gastrointestinal Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
11-C-0096
Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
No longer recruiting/follow-up only
18-125 Years
NCI
Cancer
11-C-0061
Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors
No longer recruiting/follow-up only
18-125 Years
NCI
Cancer
10-I-0148
Natural History of Severe Allergic Inflammation and Reactions
Participants currently recruited/enrolled
2-80 Years
NIAID
Hereditary
10-I-0014
The Natural History of Severe Viral Infections and Characterization of Immune Defects
Participants currently recruited/enrolled
2-125 Years
NIAID
Hereditary
10-H-0154
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused with a Reduced Dose of Non-Mobilized Donor T-Cells
Participants currently recruited/enrolled
4-80 Years
NHLBI
Cancer
10-H-0141
A Phase II Study of Ofatumumab-Based Induction Chemoimmunotherapy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
No longer recruiting/follow-up only
18-99 Years
NHLBI
Cancer
10-E-0129
Study of the Effect of Innate Immunity on the Inflammatory Response to Endotoxin
Participants currently recruited/enrolled
18-125 Years
NIEHS
Cancer
10-DK-0102
Clinical and Genetic Studies in Familial Non-Medullary Thyroid Cancer
Participants currently recruited/enrolled
7-125 Years
NIDDK
Hereditary
10-C-0174
Related and Unrelated Donor Hematopoietic Stem Cell Transplant for DOCK8 Deficiency
Participants currently recruited/enrolled
4-125 Years
NCI
Cancer
10-C-0166
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
Participants currently recruited/enrolled
18-72 Years
NCI
Cancer
10-C-0114
A Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Hereditary
10-C-0086
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies
Participants currently recruited/enrolled
0-125 Years
NCI
Cancer
10-C-0066
A Study of Hairy Cell and other Leukemias with a Focus on Recombinant Immunotoxins for Cancer Treatment
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
10-C-0054
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells from the Original Transplant Donor to Patients with Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
No longer recruiting/follow-up only
18-75 Years
NCI
Cancer
10-C-0025
Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Participants currently recruited/enrolled
18-125 Years
NCI
Cancer
09-NR-0088
Molecular-Genetic Correlates of Fatigue in Cancer Patients Receiving Localized External Beam Radiation Therapy
Completed Study; data analyses ongoing
18-125 Years
NINR
Prostate
09-I-0200
A Phase I Study of MozobilTM in the Treatment of Patients with WHIMS
Participants currently recruited/enrolled
18-75 Years
NIAID
Cancer
09-C-0242
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Participants currently recruited/enrolled
4-125 Years
NCI
Cancer
09-C-0120
An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin
Completed Study; data analyses ongoing
18-125 Years
NCI
Prostate
09-C-0100
A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
09-C-0019
A Phase I Study of Dasatinib in Combination with Bevacizumab in Advanced Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Cancer
08-H-0186
Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with Bortezomib
Completed Study; data analyses ongoing
18-70 Years
NHLBI
Cancer
07-C-0195
Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Trea
Completed Study; data analyses ongoing
18-74 Years
NCI
Cancer
07-C-0121
Phase 2 Study of the C-Met RTK Inhibitor Foretinib (Formerly GSK 1363089) in Subjects with Papillary Renal Cell Carcinoma (PRC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Hereditary
07-C-0107
A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC /TRICOM and Flutamide, vs. Flutamide Alone in Men with Androgen Insensitive, Non Metastatic (D0.5) Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Prostate
06-C-0014
Prospective Evaluation of Genetic and Epigenetic Alterations in Patients with Thoracic Malignancies
Participants currently recruited/enrolled
2-125 Years
NCI
Cancer
05-CC-0091
Electromagnetic Tracking of Devices During Interventional Procedures
Enrolling by Invitation
18-125 Years
CC
Prostate
04-I-0286
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Participants currently recruited/enrolled
1-100 Years
NIAID
Hereditary
04-HG-0211
Analysis of Specimens from Individuals with Pulmonary Fibrosis
Participants currently recruited/enrolled
18-125 Years
NHGRI
Hereditary
04-H-0012
Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples from Patients with Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members
Participants currently recruited/enrolled
2-125 Years
NHLBI
Cancer
04-C-0274
Follow-Up Study of Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic Agents
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
04-C-0102
Hematologic Malignancy Biology Study
Enrolling by Invitation
1-75 Years
NCI
Cancer
03-H-0282
Characterization of Cardiac Function in Subjects with Hereditary Hemochromatosis Who Are New York Heart Association Functional Class I
Completed Study; data analyses ongoing
21-100 Years
NHLBI
Hereditary
03-H-0105
The Determination of Genetic Basis Of Immunodeficiency
Participants currently recruited/enrolled
0-125 Years
NHLBI
Hereditary
03-AR-0131
Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
Completed Study; data analyses ongoing
18-125 Years
NIAMS
Hereditary
02-H-0250
A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning with Campath-1H
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Cancer
02-C-0313
Cancer Risk in Xeroderma Pigmentosum Heterozygotes
Participants currently recruited/enrolled
0-99 Years
NCI
Cancer
02-C-0210
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node Malignancy
Participants currently recruited/enrolled
0-125 Years
NCI
Cancer
02-C-0179
Biospecimen Acquisition from Human Subjects
Participants currently recruited/enrolled
18-125 Years
NCI
Prostate
02-C-0178
Multidisciplinary Etiologic Study of Familial Testicular Cancer
No longer recruiting/follow-up only
12-125 Years
NCI
Hereditary
01-N-0206
Phenotype/Genotype Correlations in Movement Disorders
Participants currently recruited/enrolled
2-125 Years
NINDS
Hereditary
01-DC-0229
Genetic Analysis of Hereditary Disorders of Hearing and Balance
Completed Study; data analyses ongoing
0-99 Years
NIDCD
Hereditary
01-DC-0228
Clinical and Molecular Analysis of Enlarged Vestibular Aqueducts
Completed Study; data analyses ongoing
0-99 Years
NIDCD
Hereditary
01-CC-0045
Studies of Phlebotomy Therapy in Hereditary Hemochromatosis
Participants currently recruited/enrolled
18-125 Years
CC
Hereditary
01-C-0129
Eligibility Screening for the NIH Intramural Research Program Clinical Protocols
Enrolling by Invitation
0-125 Years
NCI
Prostate
01-C-0030
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
No longer recruiting/follow-up only
18-125 Years
NCI
Cancer
01-C-0009
Breast Imaging Screening Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-up Study
Completed Study; data analyses ongoing
18-100 Years
NCI
Cancer
00-N-0043
Clinical and Molecular Manifestations of Inherited Neurological Disorders
Participants currently recruited/enrolled
2-125 Years
NINDS
Hereditary
00-CH-0160
Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical Tissue
Completed Study; data analyses ongoing
3-70 Years
NICHD
Cancer
99-H-0050
Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients with Debilitating Hematologic Diseases
Completed Study; data analyses ongoing
2-80 Years
NHLBI
Cancer
97-C-0147
Collection of Serum and Tissue Samples from Patients with Biopsy-Proved or Suspected Malignant Diseases
Participants currently recruited/enrolled
2-125 Years
NCI
Hereditary
96-C-0071
Follow-up for Patients Previously Enrolled on the Center for Cancer Research Protocols
No longer recruiting/follow-up only
0-125 Years
NCI
Prostate
93-I-0063
Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated with an Expansion of CD4-8-/TCR alpha/beta+ T Cells
Participants currently recruited/enrolled
0-99 Years
NIAID
Cancer
89-C-0086
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
Participants currently recruited/enrolled
2-125 Years
NCI
Hereditary